kynurenine has been researched along with Neoplasms in 99 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In particular, the activation of the kynurenine pathway of tryptophan degradation due to inflammation may play a key role in the development and persistence of both diseases." | 9.01 | Inflammation in cancer and depression: a starring role for the kynurenine pathway. ( Mondelli, V; Nettis, MA; Pariante, CM; Sforzini, L, 2019) |
| "Many patients with cancer suffer from anemia, depression, and an impaired quality of life (QoL)." | 6.66 | Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer. ( Egger, EM; Fuchs, D; Kink, P; Kurz, K; Lanser, L; Weiss, G; Willenbacher, W, 2020) |
| "In these symptoms, AIDS resembles classical pellagra due to dietary deficiency of Trp and niacin." | 6.38 | Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. ( Borden, EC; Brown, RR; Datta, SP; Malone, DG; Ozaki, Y; Sondel, PM, 1991) |
| " In particular, the activation of the kynurenine pathway of tryptophan degradation due to inflammation may play a key role in the development and persistence of both diseases." | 5.01 | Inflammation in cancer and depression: a starring role for the kynurenine pathway. ( Mondelli, V; Nettis, MA; Pariante, CM; Sforzini, L, 2019) |
| "Tryptophan metabolism is critical for cell proliferation, inflammation and immunoregulation." | 4.91 | The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment. ( Becker, K; Fuchs, D; Gostner, JM; Überall, F, 2015) |
| "Alterations of these enzymes in cancers can shift the balance and lead to an increased production of specific byproducts that can function as oncometabolites." | 3.01 | Tryptophan and its metabolites in normal physiology and cancer etiology. ( Barnes, S; Conacci-Sorrell, M; Garcia, R; Perez-Castro, L; Venkateswaran, N, 2023) |
| "Upregulation of IDO1 correlates with cancer aggression, poor prognosis and shortened patient survival." | 3.01 | Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated. ( Charehjoo, A; Majidpoor, J; Mortezaee, K, 2023) |
| " This study investigated the safety, tolerability and pharmacokinetics of navoximod alone and in combination with atezolizumab in Japanese patients with advanced solid tumours." | 2.94 | Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours. ( Ebata, T; Fujiwara, Y; Inatani, M; Iwasa, S; Kitano, S; Kondo, S; Koyama, T; Nakai, K; Sato, N; Shimizu, T; Shimomura, A; Tamura, K; Yamamoto, N; Yonemori, K, 2020) |
| "Kynurenine promotes T Reg (regulatory) differentiation, which leads to increased production of anti-inflammatory cytokines and suppression of cytotoxic activity of T cells." | 2.72 | The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. ( Ala, M, 2021) |
| "The development of drug resistance in tumors is a major obstacle to effective cancer chemotherapy and represents one of the most significant complications to improving long-term patient outcomes." | 2.72 | Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration. ( Feun, LG; Nguyen, DJM; Savaraj, N; Spector, SA; Theodoropoulos, G; Wangpaichitr, M; Wu, C, 2021) |
| "Many patients with cancer suffer from anemia, depression, and an impaired quality of life (QoL)." | 2.66 | Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer. ( Egger, EM; Fuchs, D; Kink, P; Kurz, K; Lanser, L; Weiss, G; Willenbacher, W, 2020) |
| "Significant progress has been made in cancer immunotherapy with checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)-programmed death-ligand 1 signaling pathways." | 2.61 | Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. ( Bao, R; Labadie, BW; Luke, JJ, 2019) |
| "However, without Trp, tumors cannot achieve an immune escape through either enzyme." | 2.58 | Targeting tryptophan availability to tumors: the answer to immune escape? ( Badawy, AA, 2018) |
| "A series of human cancers over-express IDO1 in a constitutive way." | 2.55 | IDO1: An important immunotherapy target in cancer treatment. ( Li, F; Li, S; Liu, J; Zhang, R, 2017) |
| "In the field of psychiatric disorders, namely in schizophrenia and depression, the role of IDO is linked to immune dysregulation." | 2.52 | [Indoleamine 2,3-dioxygenase in oncology and psychiatry]. ( Horáček, J; Vonka, V, 2015) |
| "IDO can be expressed by tumors themselves, but, in addition, its natural site of expression is the host immune cells recruited by the tumor (particularly dendritic cells and macrophages)." | 2.48 | Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. ( Johnson, TS; Munn, DH, 2012) |
| "In these symptoms, AIDS resembles classical pellagra due to dietary deficiency of Trp and niacin." | 2.38 | Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. ( Borden, EC; Brown, RR; Datta, SP; Malone, DG; Ozaki, Y; Sondel, PM, 1991) |
| "Malignant tumors often escape anticancer immune surveillance by suppressing the cytotoxic functions of T lymphocytes." | 1.91 | L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes. ( Abooali, M; Berger, SM; Cholewa, D; Fasler-Kan, E; Gibbs, BF; Klenova, E; Lall, GS; Milošević, M; Ruggiero, S; Schlichtner, S; Sumbayev, VV; Yasinska, IM, 2023) |
| "Tumors are heterogeneous cellular environments with entwined metabolic dependencies." | 1.72 | A pan-cancer metabolic atlas of the tumor microenvironment. ( Baruah, P; Ghoshdastider, U; Kulshrestha, T; Rohatgi, N; Skanderup, AJ, 2022) |
| "Discovery of novel strategies for cancer immunotherapy including natural small molecules is needed." | 1.72 | Icariside I - A novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape. ( Cao, Z; Chen, C; Chen, G; Huang, J; Huang, M; Lei, H; Lu, Y; Ma, Y; Song, Y; Wu, F; Zhang, C; Zhang, L; Zhao, Y; Zhou, J, 2022) |
| "Multidrug resistant cancer cells are hard to eradicate for the inefficacy of conventional anticancer drugs." | 1.42 | An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. ( Buondonno, I; Campia, I; Castella, B; Gazzano, E; Ghigo, D; Kopecka, J; Riganti, C; Rolando, B, 2015) |
| "A total of 971 incident cancer cases (507 men and 464 women) were identified over a median follow-up time of 12 years." | 1.40 | Interferon-γ-induced inflammatory markers and the risk of cancer: the Hordaland Health Study. ( Eussen, SJ; Meyer, K; Midttun, Ø; Nygård, O; Tell, GS; Ueland, PM; Ulvik, A; Vollset, SE; Zuo, H, 2014) |
| "Malignant tumors arise, in part, because the immune system does not adequately recognize and destroy them." | 1.36 | Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. ( Bowman, KJ; Burn, TC; Combs, AP; Fridman, JS; Haley, PJ; Hansbury, MJ; Koblish, HK; Neilan, CL; Scherle, PA; Sparks, RB; Vaddi, K; Waeltz, P; Yang, G; Yue, EW, 2010) |
| "If bladder cancer is caused by agents present in the urine, as is widely believed, this mechanism may also protect against carcinogenesis." | 1.27 | Inactivation of antiadherence effect of bladder surface glycosaminoglycans as possible mechanism for carcinogenesis. ( Anderson, K; Kaufman, JE; Parsons, CL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (16.16) | 18.7374 |
| 1990's | 1 (1.01) | 18.2507 |
| 2000's | 6 (6.06) | 29.6817 |
| 2010's | 35 (35.35) | 24.3611 |
| 2020's | 41 (41.41) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 2 |
| Hitosugi, T | 1 |
| Zhang, L | 3 |
| Zhang, S | 2 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 2 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 2 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 2 |
| Yang, C | 1 |
| Ng, CT | 1 |
| Li, D | 1 |
| Perez-Castro, L | 1 |
| Garcia, R | 1 |
| Venkateswaran, N | 1 |
| Barnes, S | 1 |
| Conacci-Sorrell, M | 1 |
| Watson, MJ | 1 |
| Delgoffe, GM | 1 |
| Peyraud, F | 1 |
| Guegan, JP | 1 |
| Bodet, D | 1 |
| Cousin, S | 1 |
| Bessede, A | 1 |
| Italiano, A | 1 |
| Fiore, A | 1 |
| Zeitler, L | 2 |
| Russier, M | 1 |
| Groß, A | 1 |
| Hiller, MK | 1 |
| Parker, JL | 1 |
| Stier, L | 1 |
| Köcher, T | 1 |
| Newstead, S | 1 |
| Murray, PJ | 2 |
| Rohatgi, N | 1 |
| Ghoshdastider, U | 1 |
| Baruah, P | 1 |
| Kulshrestha, T | 1 |
| Skanderup, AJ | 1 |
| McGovern, K | 3 |
| Castro, AC | 2 |
| Cavanaugh, J | 2 |
| Coma, S | 2 |
| Walsh, M | 1 |
| Tchaicha, J | 2 |
| Syed, S | 1 |
| Natarajan, P | 1 |
| Manfredi, M | 2 |
| Zhang, XM | 2 |
| Ecsedy, J | 1 |
| Wang, LT | 1 |
| Liu, KY | 1 |
| Wang, SN | 1 |
| Lin, MH | 1 |
| Liao, YM | 1 |
| Lin, PC | 1 |
| Huang, SK | 1 |
| Hsu, SH | 1 |
| Chiou, SS | 1 |
| Zhang, Y | 3 |
| Hu, Z | 1 |
| Zhang, J | 1 |
| Ren, C | 1 |
| Wang, Y | 1 |
| Chen, G | 1 |
| Huang, J | 1 |
| Lei, H | 1 |
| Wu, F | 1 |
| Chen, C | 1 |
| Song, Y | 1 |
| Cao, Z | 1 |
| Zhang, C | 2 |
| Ma, Y | 1 |
| Huang, M | 1 |
| Zhou, J | 1 |
| Lu, Y | 1 |
| Zhao, Y | 1 |
| Cui, J | 1 |
| Tian, Y | 1 |
| Liu, T | 2 |
| Lin, X | 1 |
| Li, L | 2 |
| Li, Z | 1 |
| Shen, L | 1 |
| Powderly, JD | 1 |
| Klempner, SJ | 1 |
| Naing, A | 1 |
| Bendell, J | 1 |
| Garrido-Laguna, I | 1 |
| Catenacci, DVT | 1 |
| Taylor, MH | 1 |
| Lee, JJ | 1 |
| Zheng, F | 1 |
| Zhou, F | 1 |
| Gong, X | 1 |
| Gowda, H | 1 |
| Beatty, GL | 1 |
| Zhou, H | 1 |
| Wen, H | 1 |
| Wang, L | 1 |
| Xu, M | 1 |
| Jia, Y | 1 |
| Duan, S | 1 |
| Di, B | 1 |
| Yu, Z | 1 |
| Hu, C | 1 |
| Charehjoo, A | 1 |
| Majidpoor, J | 1 |
| Mortezaee, K | 1 |
| Azimnasab-Sorkhabi, P | 1 |
| Soltani-Asl, M | 1 |
| Yoshinaga, TT | 1 |
| Zaidan Dagli, ML | 1 |
| Massoco, CO | 1 |
| Kfoury Junior, JR | 1 |
| Xue, C | 1 |
| Li, G | 1 |
| Zheng, Q | 1 |
| Gu, X | 1 |
| Shi, Q | 1 |
| Su, Y | 1 |
| Chu, Q | 1 |
| Yuan, X | 1 |
| Bao, Z | 1 |
| Lu, J | 2 |
| Schlichtner, S | 1 |
| Yasinska, IM | 1 |
| Klenova, E | 1 |
| Abooali, M | 1 |
| Lall, GS | 1 |
| Berger, SM | 1 |
| Ruggiero, S | 1 |
| Cholewa, D | 1 |
| Milošević, M | 1 |
| Gibbs, BF | 1 |
| Fasler-Kan, E | 1 |
| Sumbayev, VV | 1 |
| Kim, HJ | 1 |
| Moon, JH | 1 |
| Chung, SW | 1 |
| Abraham, I | 1 |
| Park, J | 1 |
| Nah, Y | 1 |
| Kim, WJ | 1 |
| Wu, D | 1 |
| Zhou, Y | 1 |
| Fu, H | 1 |
| Huang, Q | 1 |
| Qin, G | 1 |
| Lv, J | 2 |
| Lai, S | 1 |
| Zhang, H | 2 |
| Tang, K | 2 |
| Ma, J | 2 |
| Fiskesund, R | 1 |
| Zhang, X | 1 |
| Huang, B | 2 |
| Holthuijsen, DDB | 1 |
| van Roekel, EH | 1 |
| Bours, MJL | 1 |
| Ueland, PM | 3 |
| Breukink, SO | 1 |
| Janssen-Heijnen, MLG | 1 |
| Keulen, ETP | 1 |
| Gsur, A | 1 |
| Kok, DE | 1 |
| Ulvik, A | 3 |
| Weijenberg, MP | 1 |
| Eussen, SJPM | 1 |
| Günther, J | 1 |
| Däbritz, J | 1 |
| Wirthgen, E | 2 |
| Thomas, S | 1 |
| Laury-Kleintop, L | 1 |
| Prendergast, GC | 1 |
| Zhai, L | 1 |
| Ladomersky, E | 1 |
| Bell, A | 1 |
| Dussold, C | 1 |
| Cardoza, K | 1 |
| Qian, J | 1 |
| Lauing, KL | 1 |
| Wainwright, DA | 2 |
| Klar, R | 1 |
| Michel, S | 1 |
| Schell, M | 1 |
| Hinterwimmer, L | 1 |
| Zippelius, A | 1 |
| Jaschinski, F | 1 |
| Opitz, CA | 1 |
| Somarribas Patterson, LF | 1 |
| Mohapatra, SR | 1 |
| Dewi, DL | 1 |
| Sadik, A | 1 |
| Platten, M | 2 |
| Trump, S | 1 |
| Sadok, I | 1 |
| Tyszczuk-Rotko, K | 1 |
| Mroczka, R | 1 |
| Staniszewska, M | 1 |
| Hua, S | 1 |
| Chen, F | 1 |
| Wang, X | 1 |
| Gou, S | 1 |
| Riess, C | 1 |
| Schneider, B | 1 |
| Kehnscherper, H | 1 |
| Gesche, J | 1 |
| Irmscher, N | 1 |
| Shokraie, F | 1 |
| Classen, CF | 1 |
| Domanska, G | 1 |
| Zimpfer, A | 1 |
| Strüder, D | 1 |
| Junghanss, C | 1 |
| Maletzki, C | 1 |
| Lanser, L | 1 |
| Kink, P | 1 |
| Egger, EM | 1 |
| Willenbacher, W | 1 |
| Fuchs, D | 4 |
| Weiss, G | 2 |
| Kurz, K | 1 |
| Park, SY | 1 |
| Nam, JS | 1 |
| Jiang, S | 1 |
| Li, H | 3 |
| Piao, L | 1 |
| Jin, Z | 1 |
| Liu, J | 2 |
| Chen, S | 1 |
| Liu, LL | 1 |
| Shao, Y | 1 |
| Zhong, S | 1 |
| Wu, B | 1 |
| Li, W | 1 |
| Ren, J | 1 |
| Wang, H | 1 |
| Jin, R | 1 |
| Heinsberg, LW | 1 |
| Lockwood, MB | 1 |
| Jang, MK | 1 |
| Doorenbos, AZ | 1 |
| Campesato, LF | 1 |
| Budhu, S | 1 |
| Weng, CH | 1 |
| Gigoux, M | 1 |
| Cohen, IJ | 1 |
| Redmond, D | 1 |
| Mangarin, L | 1 |
| Pourpe, S | 1 |
| Liu, C | 1 |
| Zappasodi, R | 1 |
| Zamarin, D | 1 |
| Manfredi, MG | 1 |
| Merghoub, T | 1 |
| Wolchok, JD | 1 |
| Boros, F | 1 |
| Vécsei, L | 1 |
| Le Naour, J | 1 |
| Galluzzi, L | 1 |
| Zitvogel, L | 1 |
| Kroemer, G | 1 |
| Vacchelli, E | 1 |
| Heidari, F | 1 |
| Ramezani, A | 1 |
| Erfani, N | 1 |
| Razmkhah, M | 1 |
| Liu, XH | 1 |
| Zhai, XY | 1 |
| Ala, M | 1 |
| Kim, M | 1 |
| Tomek, P | 1 |
| Matsuda, A | 1 |
| Hata, A | 1 |
| Tanaka, A | 1 |
| Matsuda, H | 1 |
| Wangpaichitr, M | 1 |
| Theodoropoulos, G | 1 |
| Nguyen, DJM | 1 |
| Wu, C | 1 |
| Spector, SA | 1 |
| Feun, LG | 1 |
| Savaraj, N | 1 |
| Li, F | 1 |
| Zhang, R | 1 |
| Li, S | 1 |
| Liu, Y | 1 |
| Liang, X | 1 |
| Yin, X | 1 |
| Ji, T | 1 |
| Dong, W | 1 |
| Jin, X | 1 |
| Chen, D | 1 |
| Xie, HQ | 1 |
| Zhao, B | 1 |
| Zhao, T | 1 |
| Hu, ZW | 1 |
| Cao, X | 1 |
| Qin, FX | 1 |
| Ait-Belkacem, R | 2 |
| Bol, V | 1 |
| Hamm, G | 1 |
| Schramme, F | 1 |
| Van Den Eynde, B | 1 |
| Poncelet, L | 2 |
| Pamelard, F | 1 |
| Stauber, J | 2 |
| Gomes, B | 2 |
| Schäuble, S | 1 |
| Stavrum, AK | 1 |
| Bockwoldt, M | 1 |
| Puntervoll, P | 1 |
| Heiland, I | 1 |
| Cervenka, I | 1 |
| Agudelo, LZ | 1 |
| Ruas, JL | 1 |
| Cheong, JE | 1 |
| Sun, L | 1 |
| Badawy, AA | 1 |
| Triplett, TA | 1 |
| Garrison, KC | 1 |
| Marshall, N | 1 |
| Donkor, M | 1 |
| Blazeck, J | 1 |
| Lamb, C | 1 |
| Qerqez, A | 1 |
| Dekker, JD | 1 |
| Tanno, Y | 1 |
| Lu, WC | 1 |
| Karamitros, CS | 1 |
| Ford, K | 1 |
| Tan, B | 1 |
| Kumada, Y | 1 |
| Yamany, MS | 1 |
| Sentandreu, E | 1 |
| Fromm, G | 1 |
| Tiziani, S | 1 |
| Schreiber, TH | 1 |
| Ehrlich, LIR | 1 |
| Stone, E | 1 |
| Georgiou, G | 1 |
| Wang, W | 1 |
| Zhuang, X | 1 |
| Liu, W | 1 |
| Dong, L | 1 |
| Sun, H | 1 |
| Du, G | 1 |
| Ye, L | 1 |
| Labadie, BW | 1 |
| Bao, R | 1 |
| Luke, JJ | 1 |
| Cronin, SJF | 1 |
| Seehus, C | 1 |
| Weidinger, A | 1 |
| Talbot, S | 1 |
| Reissig, S | 1 |
| Seifert, M | 1 |
| Pierson, Y | 1 |
| McNeill, E | 1 |
| Longhi, MS | 1 |
| Turnes, BL | 1 |
| Kreslavsky, T | 1 |
| Kogler, M | 1 |
| Hoffmann, D | 1 |
| Ticevic, M | 1 |
| da Luz Scheffer, D | 1 |
| Tortola, L | 1 |
| Cikes, D | 1 |
| Jais, A | 1 |
| Rangachari, M | 1 |
| Rao, S | 1 |
| Paolino, M | 1 |
| Novatchkova, M | 1 |
| Aichinger, M | 1 |
| Barrett, L | 1 |
| Latremoliere, A | 1 |
| Wirnsberger, G | 1 |
| Lametschwandtner, G | 1 |
| Busslinger, M | 1 |
| Zicha, S | 1 |
| Latini, A | 1 |
| Robson, SC | 1 |
| Waisman, A | 1 |
| Andrews, N | 1 |
| Costigan, M | 1 |
| Channon, KM | 1 |
| Kozlov, AV | 1 |
| Tebbe, M | 1 |
| Johnsson, K | 1 |
| Woolf, CJ | 1 |
| Penninger, JM | 1 |
| Sforzini, L | 1 |
| Nettis, MA | 1 |
| Mondelli, V | 1 |
| Pariante, CM | 1 |
| Marillier, R | 1 |
| Zimmer, P | 1 |
| Joisten, N | 1 |
| Schenk, A | 1 |
| Bloch, W | 1 |
| Ning, S | 1 |
| Ghandi, M | 1 |
| Kryukov, GV | 1 |
| Gopal, S | 1 |
| Deik, A | 1 |
| Souza, A | 1 |
| Pierce, K | 1 |
| Keskula, P | 1 |
| Hernandez, D | 1 |
| Ann, J | 1 |
| Shkoza, D | 1 |
| Apfel, V | 1 |
| Zou, Y | 1 |
| Vazquez, F | 1 |
| Barretina, J | 1 |
| Pagliarini, RA | 1 |
| Galli, GG | 1 |
| Root, DE | 1 |
| Hahn, WC | 1 |
| Tsherniak, A | 1 |
| Giannakis, M | 1 |
| Schreiber, SL | 1 |
| Clish, CB | 1 |
| Garraway, LA | 1 |
| Sellers, WR | 1 |
| Ebata, T | 1 |
| Shimizu, T | 1 |
| Fujiwara, Y | 1 |
| Tamura, K | 1 |
| Kondo, S | 1 |
| Iwasa, S | 1 |
| Yonemori, K | 1 |
| Shimomura, A | 1 |
| Kitano, S | 1 |
| Koyama, T | 1 |
| Sato, N | 1 |
| Nakai, K | 1 |
| Inatani, M | 1 |
| Yamamoto, N | 1 |
| Wick, W | 1 |
| Opitz, C | 1 |
| Zuo, H | 2 |
| Tell, GS | 2 |
| Vollset, SE | 2 |
| Nygård, O | 2 |
| Midttun, Ø | 2 |
| Meyer, K | 2 |
| Eussen, SJ | 2 |
| Gostner, JM | 1 |
| Becker, K | 1 |
| Überall, F | 1 |
| Campia, I | 1 |
| Buondonno, I | 1 |
| Castella, B | 1 |
| Rolando, B | 1 |
| Kopecka, J | 1 |
| Gazzano, E | 1 |
| Ghigo, D | 1 |
| Riganti, C | 1 |
| Vonka, V | 1 |
| Horáček, J | 1 |
| Yeung, AW | 1 |
| Terentis, AC | 1 |
| King, NJ | 1 |
| Thomas, SR | 1 |
| Weinmann, H | 1 |
| Bostian, AC | 1 |
| Eoff, RL | 1 |
| Karami, P | 1 |
| Majidi, MR | 1 |
| Johari-Ahar, M | 1 |
| Barar, J | 1 |
| Omidi, Y | 1 |
| Shi, JG | 1 |
| Bowman, KJ | 2 |
| Chen, X | 1 |
| Maleski, J | 1 |
| Leopold, L | 1 |
| Yeleswaram, S | 1 |
| Macchiarulo, A | 1 |
| Camaioni, E | 1 |
| Nuti, R | 1 |
| Pellicciari, R | 1 |
| Costantino, G | 1 |
| Koblish, HK | 1 |
| Hansbury, MJ | 1 |
| Yang, G | 1 |
| Neilan, CL | 1 |
| Haley, PJ | 1 |
| Burn, TC | 1 |
| Waeltz, P | 1 |
| Sparks, RB | 1 |
| Yue, EW | 1 |
| Combs, AP | 1 |
| Scherle, PA | 1 |
| Vaddi, K | 1 |
| Fridman, JS | 1 |
| Munn, DH | 2 |
| Garber, K | 1 |
| Harden, JL | 1 |
| Egilmez, NK | 1 |
| Johnson, TS | 1 |
| SPACEK, M | 1 |
| QUAGLIARIELLO, E | 1 |
| AURICCHIO, S | 1 |
| CASALE, M | 1 |
| TANCREDI, F | 1 |
| LEPPANEN, VV | 1 |
| OKA, M | 1 |
| NAIK, VR | 1 |
| BHIDE, SV | 1 |
| TAKATORI, K | 1 |
| ISHIGURO, I | 1 |
| ASANO, S | 1 |
| KUZUYA, H | 1 |
| OKAMOTO, M | 1 |
| KONO, R | 1 |
| MORISHIMA, K | 1 |
| SHIBA, S | 1 |
| TERAWAKI, A | 1 |
| MIYATAKE, M | 1 |
| PERISSINOTTO, B | 1 |
| BENASSI, CA | 1 |
| ALLEGRI, G | 1 |
| BRYAN, GT | 1 |
| BROWN, RR | 4 |
| PRICE, JM | 1 |
| KHALAFALLAH, AS | 1 |
| ABUL-FADL, MA | 1 |
| HAGGERTY, JF | 1 |
| SULLIVAN, MX | 1 |
| Schröcksnadel, K | 1 |
| Wirleitner, B | 1 |
| Winkler, C | 2 |
| Schroecksnadel, K | 1 |
| Fiegl, M | 1 |
| Prassl, K | 1 |
| Denz, HA | 1 |
| Khan, JA | 1 |
| Forouhar, F | 1 |
| Tao, X | 1 |
| Tong, L | 1 |
| Zamanakou, M | 1 |
| Germenis, AE | 1 |
| Karanikas, V | 1 |
| Ogasawara, K | 1 |
| Nakamura, Y | 1 |
| Nakamura, J | 1 |
| Yokoyama, K | 1 |
| Ozaki, Y | 1 |
| Datta, SP | 1 |
| Borden, EC | 2 |
| Sondel, PM | 2 |
| Malone, DG | 1 |
| Kaufman, JE | 1 |
| Anderson, K | 1 |
| Parsons, CL | 1 |
| Lee, CM | 2 |
| Kohler, PC | 1 |
| Hank, JA | 1 |
| Storer, BE | 1 |
| Byrne, GI | 1 |
| Lehmann, LK | 1 |
| Kirschbaum, JG | 1 |
| Coon, WW | 1 |
| Nagler, E | 1 |
| Cozzolino, G | 1 |
| Scianaro, L | 1 |
| Dominici, G | 1 |
| Milia, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)[NCT03085914] | Phase 1/Phase 2 | 70 participants (Actual) | Interventional | 2017-05-02 | Completed | ||
| The Effects of Daily Anti-inflammatory Supplementation on Foundation Pain Index Scores in Chronic Opiate Patients[NCT05896878] | 20 participants (Anticipated) | Interventional | 2023-07-10 | Enrolling by invitation | |||
| The Study of the Relationship Between TWEAK/Fn14, JAK/STAT3 and IDO in the Immune Microenvironment of Endometrium in Repeated Implantation Failure[NCT02967419] | 60 participants (Anticipated) | Observational | 2017-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A DLT was defined as the occurrence of any of the protocol-specified toxicities occurring up to and including Day 28 for the cohorts where mFOLFOX6 and nab-paclitaxel/gemcitabine are administered and Day 21 for all other chemotherapy regimens in Phase 1, except those with a clear alternative explanation (eg, disease progression) or transient (≤ 72 hours) abnormal laboratory values without associated clinically significant signs or symptoms based on investigator determination. (NCT03085914)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A: Epa + Pembrolizumab + mFOLFOX6 | 2 |
| Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine | 0 |
| Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin | 0 |
| Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent | 0 |
| Group E: Epa + Pembrolizumab + Cyclophosphamide | 0 |
| Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent | 3 |
| Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent | 0 |
A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of epacadostat, pembrolizumab, or chemotherapy. Serious adverse event is defined as an event that meets 1 of the following criteria: is fatal or life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability, incapacity, or a substantial disruption of a person's ability to conduct normal life functions, constitutes a congenital anomaly or birth defect,is a medically important event that may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the outcomes listed above. (NCT03085914)
Timeframe: Up to 21 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAE | Serious TEAE | |
| Group A: Epa + Pembrolizumab + mFOLFOX6 | 9 | 5 |
| Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine | 9 | 5 |
| Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin | 11 | 3 |
| Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent | 9 | 6 |
| Group E: Epa + Pembrolizumab + Cyclophosphamide | 13 | 4 |
| Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent | 8 | 6 |
| Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent | 11 | 5 |
ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. (NCT03085914)
Timeframe: Up to Week 18
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete Response | Partial Response | |
| Group A: Epa + Pembrolizumab + mFOLFOX6 | 0 | 5 |
| Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine | 1 | 2 |
| Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin | 0 | 3 |
| Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent | 0 | 2 |
| Group E: Epa + Pembrolizumab + Cyclophosphamide | 0 | 3 |
| Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent | 0 | 1 |
| Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent | 0 | 5 |
40 reviews available for kynurenine and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Gene Expression Regulation, Enzymologic; Huma | 2021 |
Tryptophan and its metabolites in normal physiology and cancer etiology.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; T-Lymphocytes; Tryptophan; Tryp | 2023 |
Fighting in a wasteland: deleterious metabolites and antitumor immunity.
Topics: Adenosine; Animals; Humans; Immunotherapy; Kynurenine; Lactic Acid; Neoplasms; Reactive Oxygen Speci | 2022 |
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
Topics: Animals; Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; | 2022 |
Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Topics: Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasm | 2022 |
Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.
Topics: Ecosystem; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Tryptophan; Tumor Mi | 2023 |
IL4i1 and IDO1: Oxidases that control a tryptophan metabolic nexus in cancer.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Oxidoreductases; Tryptophan; Tu | 2023 |
Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Tryptophan; Tumor Microenvironm | 2023 |
Tryptophan metabolism in health and disease.
Topics: Dioxygenases; Humans; Kynurenine; Neoplasms; Tryptophan | 2023 |
Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment.
Topics: Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasm | 2019 |
The therapeutic potential of targeting tryptophan catabolism in cancer.
Topics: Animals; Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; | 2020 |
Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer.
Topics: Anemia; Animals; Depression; Fatigue; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; Ky | 2020 |
Systematic Review of the Kynurenine Pathway and Psychoneurological Symptoms Among Adult Cancer Survivors.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cancer Survivors; Female; Humans; Kynurenic Acid; Kynure | 2020 |
Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs.
Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Drug Development; Humans; Kynurenine; Neoplasms | 2020 |
Trial watch: IDO inhibitors in cancer therapy.
Topics: Animals; Enzyme Inhibitors; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Tryptophan | 2020 |
Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases.
Topics: Adjuvants, Immunologic; Humans; Immune System Diseases; Immunologic Factors; Indoleamine-Pyrrole 2,3 | 2022 |
Role of tryptophan metabolism in cancers and therapeutic implications.
Topics: Humans; Immune Tolerance; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasm Proteins; Neopl | 2021 |
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kyn | 2021 |
Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Enzyme Inhibitors; Humans; Immunotherapy; Indolea | 2021 |
Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration.
Topics: Cisplatin; Drug Resistance, Neoplasm; Energy Metabolism; Glycolysis; Humans; Kynurenine; Mitochondri | 2021 |
IDO1: An important immunotherapy target in cancer treatment.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Immu | 2017 |
Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health.
Topics: Brain; Depression; Exercise; Gastrointestinal Microbiome; Gastrointestinal Tract; Humans; Inflammati | 2017 |
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Topics: Animals; Antineoplastic Agents; Humans; Immunosuppressive Agents; Immunotherapy; Indoleamine-Pyrrole | 2018 |
Targeting tryptophan availability to tumors: the answer to immune escape?
Topics: Albumins; Animals; Biomarkers; Fatty Acids; Humans; Kynurenine; Metabolic Networks and Pathways; Mol | 2018 |
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Topics: Cell Line, Tumor; Computational Biology; Enzyme Inhibitors; Gene Expression Profiling; Humans; Immun | 2019 |
Inflammation in cancer and depression: a starring role for the kynurenine pathway.
Topics: Antidepressive Agents; Depression; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infl | 2019 |
[Immune modulation by tryptophan metabolism: relevance for autoimmune and tumor diseases].
Topics: Animals; Autoimmune Diseases; Brain; Dietary Supplements; Disease Models, Animal; Dose-Response Rela | 2013 |
The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Topics: Animals; Cell Proliferation; Dendritic Cells; Humans; Immunity, Cellular; Immunotherapy; Indoleamine | 2015 |
[Indoleamine 2,3-dioxygenase in oncology and psychiatry].
Topics: Brain; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-gamma; Kynurenine; Mental Disorders; | 2015 |
Role of indoleamine 2,3-dioxygenase in health and disease.
Topics: Animals; Bacterial Infections; Catalysis; Gene Expression Regulation, Enzymologic; Humans; Indoleami | 2015 |
Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.
Topics: Adenosine; Humans; Immunotherapy; Kynurenine; Neoplasms; Protein Serine-Threonine Kinases; Receptor, | 2016 |
Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Topics: Animals; Crystallography, X-Ray; Enzyme Activation; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2 | 2009 |
New promises for manipulation of kynurenine pathway in cancer and neurological diseases.
Topics: Animals; Drug Delivery Systems; Drug Discovery; Humans; Huntington Disease; Indoleamine-Pyrrole 2,3, | 2009 |
Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity.
Topics: Animals; Autoimmunity; Cell Lineage; Dendritic Cells; Gene Expression Regulation; Humans; Immune Tol | 2012 |
Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.
Topics: Animals; Antineoplastic Agents; Dendritic Cells; Enzyme Inhibitors; Humans; Immune Tolerance; Indole | 2012 |
Monitoring tryptophan metabolism in chronic immune activation.
Topics: Autoimmune Diseases; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infections; Kynurenine; Neoplasms | 2006 |
Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery.
Topics: Acrylamides; Adenosine Diphosphate Ribose; Aging; Animals; Antineoplastic Agents; Autoimmune Disease | 2007 |
Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Topics: Animals; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; T-Lymphocytes; Tryptop | 2007 |
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Autoimmune Diseases; Enzyme Induction; Female; Humans; Indoleami | 1991 |
3 trials available for kynurenine and Neoplasms
| Article | Year |
|---|---|
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Kynurenine; Neoplasms; Programmed Cell Death | 2022 |
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian Peopl | 2020 |
Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.
Topics: Adult; Aged; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Male; Middle Aged; Mo | 2017 |
56 other studies available for kynurenine and Neoplasms
| Article | Year |
|---|---|
Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling.
Topics: Amino Acid Transport System y+; Ferroptosis; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenin | 2022 |
A pan-cancer metabolic atlas of the tumor microenvironment.
Topics: Cell Line, Tumor; Humans; Kynurenine; Neoplasms; Stromal Cells; Tryptophan Oxygenase; Tumor Microenv | 2022 |
Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression.
Topics: Animals; Cytochrome P-450 CYP1A1; Cytokines; Humans; Immunosuppression Therapy; Kynurenine; Mice; Ne | 2022 |
Aryl hydrocarbon receptor-kynurenine axis promotes oncogenic activity in BCP-ALL.
Topics: Animals; Humans; Kynurenine; Mice; Neoplasms; Polycyclic Aromatic Hydrocarbons; Receptors, Aryl Hydr | 2023 |
Icariside I - A novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape.
Topics: Animals; Cell Line, Tumor; Flavones; Immunotherapy; Kynurenine; Mice; Neoplasms; Programmed Cell Dea | 2022 |
Pancancer Analysis of Revealed
Topics: B7 Antigens; Biomarkers, Tumor; DNA; Humans; Immunotherapy; Kynurenine; Methyltransferases; Microsat | 2022 |
Label-free tumor cell screening based on IDO1-mediated tryptophan metabolism at single cell level.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Oxidation-Reduction; Tryptophan | 2022 |
L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes.
Topics: Humans; Immune Evasion; Kynurenine; Neoplasms; Signal Transduction; T-Lymphocytes; Tumor Microenviro | 2023 |
The role of cytokines and Indolamine-2.3 dioxygenase in experiencing a psycho-neurological symptom cluster in hematological cancer patients: IL-1alpha, IL-1beta, IL-4, IL-6, TNF-alpha, kynurenine, and tryptophan.
Topics: Cytokines; Dioxygenases; Hematologic Neoplasms; Humans; Interleukin-4; Interleukin-6; Kynurenine; Ne | 2023 |
IDO-triggered swellable polymeric micelles for IDO inhibition and targeted cancer immunotherapy.
Topics: Drug Delivery Systems; Humans; Immunotherapy; Kynurenine; Micelles; Neoplasms; Tryptophan; Tumor Mic | 2023 |
Tumor cell-released kynurenine biases MEP differentiation into megakaryocytes in individuals with cancer by activating AhR-RUNX1.
Topics: Animals; Bias; Cell Differentiation; Core Binding Factor Alpha 2 Subunit; Erythroid Precursor Cells; | 2023 |
Longitudinal associations of macronutrient and micronutrient intake with plasma kynurenines in colorectal cancer survivors up to 12 months posttreatment.
Topics: Eating; Humans; Kynurenic Acid; Kynurenine; Micronutrients; Neoplasms; Nutrients; Prospective Studie | 2023 |
Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissues.
Topics: Animals; Antibodies, Monoclonal; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fluoresc | 2019 |
Quantification of IDO1 enzyme activity in normal and malignant tissues.
Topics: Animals; Enzyme Assays; HeLa Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Mice; | 2019 |
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Screening As | 2020 |
Simultaneous voltammetric analysis of tryptophan and kynurenine in culture medium from human cancer cells.
Topics: Biosensing Techniques; Boron; Cell Culture Techniques; Cell Line, Tumor; Chromatography, High Pressu | 2020 |
Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Drug Design; Drug Scre | 2020 |
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Cell Line | 2020 |
Kynurenine pathway enzyme KMO in cancer progression: A tip of the Iceberg.
Topics: Humans; Kynurenine; Neoplasms | 2020 |
Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Crystallography, X-Ray; Drug Discovery; Female; | 2020 |
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Topics: Animals; Drug Resistance, Neoplasm; Humans; Immune Tolerance; Immunotherapy; Indoleamine-Pyrrole 2,3 | 2020 |
Canine mast cell tumour cells regulate tryptophan catabolism via the expression of indoleamine 2,3-dioxygenase.
Topics: Animals; Cell Line, Tumor; Dog Diseases; Dogs; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynuren | 2021 |
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Fem | 2017 |
Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology.
Topics: Animals; Cell Line, Tumor; Imaging, Three-Dimensional; Kynurenine; Mass Spectrometry; Mice; Neoplasm | 2017 |
SBMLmod: a Python-based web application and web service for efficient data integration and model simulation.
Topics: Cell Line, Tumor; Humans; Internet; Kynurenine; Models, Theoretical; Neoplasms; Serotonin; Tryptopha | 2017 |
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Topics: Adjuvants, Immunologic; Animals; Cancer Vaccines; Cell Line, Tumor; Humans; Hydrolases; Indoleamine- | 2018 |
Determination of kynurnine and tryptophan, biomarkers of indoleamine 2,3-dioxygenase by LC-MS/MS in plasma and tumor.
Topics: Animals; Biomarkers; Blood Chemical Analysis; Chromatography, Liquid; Indoleamine-Pyrrole 2,3,-Dioxy | 2018 |
The metabolite BH4 controls T cell proliferation in autoimmunity and cancer.
Topics: Administration, Oral; Alcohol Oxidoreductases; Animals; Autoimmune Diseases; Biopterins; Cell Line, | 2018 |
Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
Topics: Animals; Chromatography, Liquid; Disease Models, Animal; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynur | 2019 |
Impact of physical exercise on the kynurenine pathway in patients with cancer: current limitations and future perspectives.
Topics: Depression; Depressive Disorder; Exercise; Humans; Kynurenine; Neoplasms | 2019 |
The landscape of cancer cell line metabolism.
Topics: Animals; Asparaginase; Asparagine; Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor; Cell Lin | 2019 |
Interferon-γ-induced inflammatory markers and the risk of cancer: the Hordaland Health Study.
Topics: Adult; Aged; Biomarkers, Tumor; C-Reactive Protein; Female; Follow-Up Studies; Humans; Inflammation; | 2014 |
Markers of vitamin B6 status and metabolism as predictors of incident cancer: the Hordaland Health Study.
Topics: Aged; Biomarkers; Female; Follow-Up Studies; Health Surveys; Humans; Incidence; Kynurenine; Male; Mi | 2015 |
An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells.
Topics: Animals; Autocrine Communication; Cell Line, Tumor; Cytokines; Down-Regulation; Drug Resistance, Neo | 2015 |
Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas.
Topics: DNA Replication; Genomic Instability; Glioma; Humans; Kynurenine; Neoplasms; Signal Transduction | 2016 |
Development of screen-printed tryptophan-kynurenine immunosensor for in vitro assay of kynurenine-mediated immunosuppression effect of cancer cells on activated T-cells.
Topics: Antibodies, Immobilized; Biosensing Techniques; Cell Line, Tumor; Electrodes; Equipment Design; Gold | 2017 |
Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Topics: Amidines; Animals; Cell Line, Tumor; Dogs; Enzyme Inhibitors; Female; Humans; Immune System; Immunot | 2010 |
Indoleamine 2,3-dioxygenase, Tregs and cancer.
Topics: Animals; Enzyme Inhibitors; Forkhead Transcription Factors; Humans; Immune Tolerance; Indoleamine-Py | 2011 |
Evading immunity: new enzyme implicated in cancer.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kyn | 2012 |
Kynurenine in disease, with particular reference to cancer.
Topics: Body Fluids; Kynurenine; Neoplasms; Urine | 1955 |
[Certain metabolic peculiarities observed in individuals with tumors of the bladder; preventive note].
Topics: Aminobenzoates; Humans; Kynurenine; Neoplasms; Urinary Bladder Neoplasms | 1958 |
Metabolism of tryptophan in cancer of various sites.
Topics: Indoleacetic Acids; Kynurenine; Neoplasms; ortho-Aminobenzoates; Tryptophan; Xanthurenates | 1963 |
PRELIMINARY STUDIES ON TRYPTOPHAN PYRROLASE ACTIVITY IN MICE.
Topics: Adenocarcinoma; Animals; Kynurenine; Liver; Mice; Neoplasms; Neoplasms, Experimental; Oxidation-Redu | 1963 |
[BIOCHEMICAL STUDIES ON THE METABOLISM OF THE TUMOR BEARING ANIMALS. II. RESEARCHES FOR THE AMINO ACIDS IN THE URINE OF THE RATS FED ON THE DAB-RICE].
Topics: Amino Acids; Chromatography; Kynurenine; Liver Neoplasms; Neoplasms; Neoplasms, Experimental; p-Dime | 1963 |
STUDIES ON THE TRYPTOPHAN METABOLISM IN TUMOR-BEARING ANIMALS.
Topics: Animals; Kynurenic Acid; Kynurenine; Liver; Neoplasms; Neoplasms, Experimental; Niacin; Nicotinic Ac | 1964 |
URINARY EXCRETION OF TRYPTOPHAN METABOLITES IN PATIENTS WITH RENAL PELVIS AND PARENCHYMA TUMOURS.
Topics: Chromatography; Humans; Kidney Neoplasms; Kidney Pelvis; Kynurenic Acid; Kynurenine; Neoplasms; orth | 1964 |
MOUSE BLADDER CARCINOGENICITY OF CERTAIN TRYPTOPHAN METABOLITES AND OTHER AROMATIC NITROGEN COMPOUNDS SUSPENDED IN CHOLESTEROL.
Topics: Amines; Animals; Carcinogens; Cholesterol; Fluorenes; Hydroxylamines; Kynurenic Acid; Kynurenine; Me | 1964 |
STUDIES ON THE URINARY EXCRETION OF CERTAIN TRYPTOPHAN METABOLITES BEFORE AND AFTER TRYPTOPHAN LOADING DOSE IN BILHARZIASIS, BILHARZIAL BLADDER CANCER AND CERTAIN OTHER TYPES OF MALIGNANCIES IN EGYPT.
Topics: Amino Acids; Egypt; Epidemiology; Fluids and Secretions; Humans; Hydroxyindoleacetic Acid; Indoleace | 1964 |
Kynurenine accumulation in tumor-bearing mice.
Topics: Animals; Kynurenine; Mice; Neoplasms | 1960 |
Diminished quality of life in patients with cancer correlates with tryptophan degradation.
Topics: Aged; Disease Progression; Fatigue; Female; Humans; Immunity, Cellular; Karnofsky Performance Status | 2007 |
Studies on tryptophan metabolism in malignant tumor.
Topics: Animals; Chromatography, Paper; Humans; Kynurenine; Mucoproteins; Neoplasms; Radiation Effects; Rats | 1967 |
Inactivation of antiadherence effect of bladder surface glycosaminoglycans as possible mechanism for carcinogenesis.
Topics: 3-Hydroxyanthranilic Acid; Animals; Bacterial Adhesion; Cyclamates; Glycosaminoglycans; Kynurenine; | 1987 |
Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.
Topics: Biopterins; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Interleukin-2; Kynurenine; Ne | 1989 |
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity.
Topics: Carcinoma; Cells, Cultured; Fibroblasts; Humans; Interferon beta-1a; Interferon beta-1b; Interferon | 1986 |
The tryptophan load as a test for pyridoxine deficiency in hospitalized patients.
Topics: Adult; Aged; Arteriosclerosis; Female; Gastrointestinal Diseases; Humans; Kynurenine; Male; Middle A | 1969 |
[Tryptophan-pyrrolase activity in patients with neoplasms of various types].
Topics: Humans; Kynurenine; Liver; Neoplasms; Tryptophan; Tryptophan Oxygenase | 1969 |